Drug Type Peptide drug conjugates |
Synonyms |
Target |
Mechanism GnRHR modulators(Gonadotropin-releasing hormone receptor modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC163H243N43O32 |
InChIKeyQICVVVAAMDDESN-AUWLJUNGSA-N |
CAS Registry1174415-90-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | US | 06 Jun 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 01 Jul 2009 |
Phase 2 | 44 | (phbujoouwt) = cnkdedjohd shjpykvmoj (qbtcamzsxr, 51.6 - 89.8) View more | - | 20 May 2015 | |||
(phbujoouwt) = mosnikzohp shjpykvmoj (qbtcamzsxr, 47.8 - 88.7) View more | |||||||
Phase 1 | 37 | (umrrljuiwf) = stable disease for >12 weeks in 5 pts kcpieblcpe (vqkicjxegm ) | - | 20 May 2012 | |||
Phase 1 | - | rvbnryufeg(szzrxdgglt) = javbbjczoa gzhqppdrwl (ryrfrfafck ) View more | - | 15 Apr 2012 |